MedCity News November 21, 2024
Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals’ Revuforj, which won FDA approval last week.
The FDA recently approved the first drug in a new class of leukemia medicines. Kura Oncology’s endeavor to follow that newly blazed regulatory trail is now infused with $330 million from a collaboration agreement with Kyowa Kirin.
The Kura drug, ziftomenib, has completed a Phase 2 test designed to support a new drug application that the companies expect will be submitted to the FDA in 2025 seeking approval as a...
Today's Sponsors
Today's Sponsor